Examining Allegations Against Capricor Therapeutics by Pomerantz Law Firm

Pomerantz Law Firm Investigates Capricor Therapeutics

On August 16, 2025, Pomerantz LLP announced that it is conducting an investigation on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The law firm is examining potential claims of securities fraud and possible unlawful activities conducted by certain officers and directors at Capricor.

Background

Capricor Therapeutics specializes in developing innovative therapies for rare diseases, particularly focusing on Duchenne muscular dystrophy (DMD). Their investigational product, deramiocel, is a cell therapy designed to treat DMD cardiomyopathy. The investigation follows a significant stock price decline prompted by actions taken by the U.S. Food and Drug Administration (FDA).

On May 5, 2025, Capricor reported a pivotal update regarding its Biologics License Application for deramiocel. The FDA confirmed its intent to hold an advisory committee meeting for the application, which momentarily boosted investor confidence. However, the situation dramatically changed the next day when the company’s stock plummeted by 29.13%, closing at $7.30 per share.

Decline of Investors' Trust

The downfall of Capricor's stock continued when on June 20, 2025, it became public knowledge that the new head of the FDA unit responsible for evaluating deramiocel had decided to cancel the scheduled advisory committee meeting. This news stemmed from rising uncertainties regarding the drug’s efficacy and safety. The immediate result was a staggering decrease of 30.82% in Capricor’s stock price, bringing it down to $8.26 per share.

The Role of Pomerantz LLP

Pomerantz LLP, recognized for its expertise in corporate and securities class litigation, takes an assertive stance in protecting investor rights. Founded by the esteemed Abraham L. Pomerantz, the firm has earned a robust reputation for representing victims of securities fraud and corporate malfeasance. The firm’s history spans over 85 years, having secured numerous victories that led to substantial financial recoveries for class members. Their ongoing investigation seeks to explore if Capricor misled investors or engaged in illegal business practices.

Investors who feel they have suffered losses as a result of Capricor's stock declines are encouraged to reach out to Pomerantz LLP for further information about the investigation and possible participation in a class-action lawsuit. Those interested can contact Danielle Peyton directly at the provided contact details for guidance and more information.

Conclusion

As the investigation unfolds, it particularly shines a spotlight on the necessity for companies, especially in the biotechnology sector, to maintain transparency with their investors. The unfolding of these events serves as a reminder of the inherent risks associated with investing in companies dealing with high-stakes medical products and therapies that are subject to regulatory scrutiny. As always, the actions taken by the firms representing investors will play a crucial role in ensuring accountability in the financial system.

For more details, reach out to Pomerantz LLP at email protected] or call 646-581-9980, extension 7980. Those affected can also visit [Pomerantz’s website for further insights into the firm’s approach and track record in handling such sensitive matters.